➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
McKesson
Baxter
Moodys
Colorcon

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 9,987,326

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,987,326
Title:Klotho protein and related compounds for the treatment and diagnosis of cancer
Abstract: Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents.
Inventor(s): Koeffler; H. Phillip (Los Angeles, CA), Wolf; Ido (Or Yehuda, IL), Rubinek; Tamar (Or Yehuda, IL), Kaufman; Bella (Kiryat Ono, IL), Abramovitch; Lilach (Kfar Saba, IL)
Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd. (Ramat Gan, IL) CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA)
Application Number:13/419,610
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,987,326
Patent Claims:see list of patent claims

Details for Patent 9,987,326

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Tel HaShomer Medical Research Infrastructure and Services Ltd. (Ramat Gan, IL) CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA) 2039-02-26 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Tel HaShomer Medical Research Infrastructure and Services Ltd. (Ramat Gan, IL) CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA) 2039-02-26 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Tel HaShomer Medical Research Infrastructure and Services Ltd. (Ramat Gan, IL) CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA) 2039-02-26 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Tel HaShomer Medical Research Infrastructure and Services Ltd. (Ramat Gan, IL) CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA) 2039-02-26 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Tel HaShomer Medical Research Infrastructure and Services Ltd. (Ramat Gan, IL) CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA) 2039-02-26 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial Tel HaShomer Medical Research Infrastructure and Services Ltd. (Ramat Gan, IL) CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Moodys
Medtronic
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.